Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multinational, Open-Label, Single-Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures.

Next Previous
Trial Profile

A Prospective, Multinational, Open-Label, Single-Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacosamide (Primary) ; Levetiracetam
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms OCToPOS; VERVE
  • Sponsors UCB

Most Recent Events

  • 24 May 2017 Planned locations also included Austria, Canada, Hungary, Netherlands, Switzerland.
  • 01 Apr 2017 Results assessing efficacy and of post hoc analysis (n=51) assessing effectiveness of LCM among patients treated within dose range (less than or equal to 400 Mg/ Day), published in the Acta Neurologica Scandinavica
  • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top